Brokerages forecast that ABIOMED, Inc. (NASDAQ:ABMD) will post $0.73 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for ABIOMED’s earnings, with estimates ranging from $0.68 to $0.78. ABIOMED reported earnings of $0.44 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 65.9%. The business is scheduled to issue its next quarterly earnings results on Thursday, October 25th.

On average, analysts expect that ABIOMED will report full year earnings of $4.57 per share for the current financial year, with EPS estimates ranging from $4.43 to $4.70. For the next year, analysts expect that the company will report earnings of $4.72 per share, with EPS estimates ranging from $4.50 to $5.36. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow ABIOMED.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $1.15. ABIOMED had a net margin of 25.71% and a return on equity of 18.91%. The firm had revenue of $180.01 million during the quarter, compared to analysts’ expectations of $173.87 million. During the same period in the previous year, the company earned $0.82 earnings per share. ABIOMED’s quarterly revenue was up 35.9% compared to the same quarter last year.

A number of brokerages recently weighed in on ABMD. BidaskClub cut shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 18th. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $457.00 price target for the company in a research report on Tuesday, July 10th. ValuEngine cut shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Piper Jaffray Companies boosted their price target on shares of ABIOMED from $360.00 to $480.00 and gave the company an “overweight” rating in a research report on Friday, June 22nd. Finally, Jefferies Financial Group boosted their price target on shares of ABIOMED to $460.00 and gave the company a “buy” rating in a research report on Tuesday, May 29th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. ABIOMED currently has a consensus rating of “Buy” and an average price target of $374.88.

ABMD traded up $4.75 on Tuesday, reaching $411.33. The company had a trading volume of 20,129 shares, compared to its average volume of 442,446. ABIOMED has a 1 year low of $144.01 and a 1 year high of $450.93. The stock has a market cap of $18.25 billion, a PE ratio of 167.96, a price-to-earnings-growth ratio of 4.36 and a beta of -0.08.

In other news, COO David M. Weber sold 46,500 shares of the company’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $442.63, for a total value of $20,582,295.00. Following the completion of the sale, the chief operating officer now directly owns 189,657 shares of the company’s stock, valued at $83,947,877.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Andrew J. Greenfield sold 4,440 shares of the company’s stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $395.00, for a total transaction of $1,753,800.00. The disclosure for this sale can be found here. Insiders sold 175,222 shares of company stock valued at $75,382,784 over the last ninety days. Corporate insiders own 3.50% of the company’s stock.

Large investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in shares of ABIOMED by 65.0% in the second quarter. Wells Fargo & Company MN now owns 134,542 shares of the medical equipment provider’s stock valued at $55,034,000 after buying an additional 52,986 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of ABIOMED in the second quarter valued at about $1,515,000. Columbus Circle Investors raised its holdings in shares of ABIOMED by 179.7% in the second quarter. Columbus Circle Investors now owns 64,442 shares of the medical equipment provider’s stock valued at $26,360,000 after buying an additional 41,403 shares during the last quarter. Bank of Montreal Can purchased a new position in ABIOMED during the second quarter worth about $11,530,000. Finally, Janney Montgomery Scott LLC raised its holdings in ABIOMED by 16.3% during the second quarter. Janney Montgomery Scott LLC now owns 2,039 shares of the medical equipment provider’s stock worth $834,000 after purchasing an additional 286 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: Marijuana Stocks

Get a free copy of the Zacks research report on ABIOMED (ABMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.